Last reviewed · How we verify
Docetaxel (XRP6976)
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Docetaxel (XRP6976) |
|---|---|
| Also known as | Taxotere®, Taxotere |
| Sponsor | Sanofi |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that binds to the β-subunit of tubulin dimers and promotes microtubule assembly while inhibiting disassembly. This leads to accumulation of stable microtubules and disruption of the dynamic microtubule network required for cell division, ultimately triggering apoptosis in cancer cells. It is effective against a broad range of solid tumors.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Alopecia
- Nausea/vomiting
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer (PHASE3)
- Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE3)
- Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (PHASE2)
- Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck (PHASE2)
- Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents (PHASE2)
- Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer (PHASE2)
- A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA) (PHASE3)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel (XRP6976) CI brief — competitive landscape report
- Docetaxel (XRP6976) updates RSS · CI watch RSS
- Sanofi portfolio CI